openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizie

News

Discover

Markets

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizie

fibrodysplasia ossificans progressiva — news, coverage & facts — IJR

|NewsJournalsTopicfibrodysplasia ossificans progressiva

fibrodysplasia ossificans progressiva

Topic

fibrodysplasia ossificans progressiva

0 members

Feed News Media Community Answers Map About

1 mentions · 24hcoverage spread: L21/C21/R57

Comments

Ask this entity anything:

Free account · your comment posts right after signup

Health
FDA Approves Regeneron Pasatru for FOP
Regeneron's garetosmab, marketed as Pasatru, received FDA approval to treat adults with fibrodysplasia ossificans progressiva, becoming the second FDA-cleared therapy for FOP and the first to reduce clinician-assessed flare-ups. Driven by OPTIMA/phase 3 data showing about 90% reduction in new bone lesions over 56 weeks and substantial decreases in flare-ups, Pasatru competes with Ipsen's Sohonos and awaits EMA/Japan submissions, with price not disclosed.
6 sources

Facts from Wikidata (CC0).

Fibrodysplasia ossificans progressiva (; FOP), also called Münchmeyer disease or formerly myositis ossificans progressiva, is an extremely rare connective tissue disease in which fibrous connective tissue such as muscle, tendons, and ligaments turn into bone tissue. It is the only known medical condition where one organ system changes into another. It is a severe, disabling disorder with no cure or treatment.

Read the full article →